口腔结肠向的pH响应的聚合物纳米颗粒加载naringin增强性性结肠炎治疗
Shilong Fan1,2, Yue Zhao1,2, Yinlian Yao1,2
1Guangdong Provincial Key laboratory of research and development of Natural drugs, School of Pharmacology, Guangdong Medical University, Dongguan, 523808, China.
Journal of translational medicine
|October 1, 2024
概括
这项研究介绍了一种用于治疗性结肠炎 (UC) 的新型口服纳米粒子输送系统. 该系统有效地向炎症的结肠组织,减少炎症和毒性,改善治疗结果.
科学领域:
- 纳米医学是一种纳米医学.
- 药物运输 药物运输 药物运输
- 胃肠病学 胃肠病学
背景情况:
- 性结肠炎 (UC) 需要有效的结肠向药物输送,以最大限度地降低全身毒性.
- 口服输送系统对于改善治疗效益和患者遵守是至关重要的.
研究的目的:
- 开发和评估一种新的,针对结肠的纳米粒子系统,用于为UC治疗提供naringin (Nar).
- 为了增强纳米粒子粘合和巨细胞向精确的药物输送.
主要方法:
- 开发负电荷的PLGA-PEG纳米颗粒封装naringin (Nar).
- 用奇托和曼诺对表面进行修改,以创建MC@Nar-NP,以改善准.
- 评估纳米粒子稳定性,胃肠道抵抗性和炎症部位的积累.
- 对抗炎症作用的评估,包括降低细胞因子水平和在体外和体内清理反应性氧物种 (ROS).
主要成果:
- 在酸性胃肠道条件下,MC@Nar-NPs表现出极好的稳定性.
- 在炎症的结肠组织中专门积累的纳米粒子.
- 在结肠中观察到的促炎性细胞因子和ROS清理的显著减少.
- 有效缓解结肠炎症,降低全身毒性.
结论:
- 开发的MC@Nar-NP为针对性UC治疗提供了一个有前途的口腔纳米医学方法.
- 该系统利用中国草药成分进行局部和精确的治疗干预.
- 为炎症性肠病中先进的口服药物输送系统提供理论基础.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
128
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
128
Peptic Ulcer Disease IV: Management
74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
372
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
372
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
360
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
360


